21:25, Mon, Oct 20, 2025 Updated: 21:28, Mon, Oct 20, 2025 Activists demanding an Islamophobia definition will use it to water down counter-terrorism policies and immigration rules, a scathing report ...
Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to ...
A member of Colorado’s second-highest court asked the state Supreme Court on Thursday to endorse one definition of “reasonable doubt” for trial judges to use — out of the three versions currently on ...
DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...
A politician has sparked outrage with an offensive remark after being asked to give his definition of a woman. Stuart Nash, a former New Zealand Labour minister- who is now a member of the New Zealand ...
Mumbai: Twenty-year-old Thanekar Maahi Rude always dreamed of becoming a doctor—someone her parents always turned to since she was born with spina bifida, a neurological birth defect. She underwent ...
Hosted on MSN
FDA Approves Dupixent for Bullous Pemphigoid
TUESDAY, June 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on ...
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...
Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.
Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced. In the study, 106 patients were randomized to 300 mg of subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback